Physician profile
Brian M Clark
NPI 1437159795
$688.79
in general payments reported to CMS, 2019-2025
10 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.32 · 2020: $16.26 · 2021: $17.02 · 2022: $75.94 · 2023: $299 · 2024: $145 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $562.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $248.62 | 2023-2025 | Myfembree |
| Aspira Women'S Health INC | $87.19 | 2022-2023 | Ova1 |
| Dilon Technologies, INC. | $85.85 | 2024 | Hemoblast Bellows |
| Mayne Pharma Commercial LLC | $78.65 | 2023 | |
| Myovant Sciences INC. | $69.63 | 2021-2022 | |
| Astellas Pharma US INC | $36.75 | 2024-2025 | Veozah |
| Organon LLC | $26.06 | 2023 | Ganirelix Acetate, Pregnyl |
| Minerva Surgical, INC | $22.46 | 2024 | |
| Dentsply Ih INC. | $17.32 | 2019 | |
| Emmaus Medical, INC. | $16.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.